Effect of erythropoiesis-stimulating agents on breast cancer patients: a meta-analysis
文献类型：期刊论文
| 作者 | Wu, Tong1,2,4; Tong, Zhenhua3; Ren, Tianshu4; Xie, Danni4; Sun, Xue4 |
| 刊名 | CLINICAL AND EXPERIMENTAL MEDICINE
 |
| 出版日期 | 2022-10-31 |
| 页码 | 13 |
| 关键词 | Breast cancer Erythropoiesis-stimulating agents Meta-analysis Mortality |
| ISSN号 | 1591-8890 |
| DOI | 10.1007/s10238-022-00921-1 |
| 通讯作者 | Sun, Xue(sunxue88@163.com) |
| 英文摘要 | Erythropoiesis-stimulating agents (ESAs) have been reported to increase the risk of death in cancer patients. In this study, we selected breast cancer, which is currently the most prevalent cancer worldwide, for a meta-analysis to re-examine the advantages and disadvantages of using ESAs. All relevant studies were searched by PubMed, Embase, Web of science, and Cochrane Library. Endpoints including mortality, incidence of thrombo-vascular events, hemoglobin, and transfusion requirements were meta-analyzed based on random-effects model or fixed-effect model. 10 studies were finally included, with a total sample size of 6785 patients. The risk of mortality was higher in patients using ESA than in controls (RR 1.07, 95% CI 1.01-1.13, P = 0.03); subgroup analysis found that the mortality rate was higher in patients treating with ESA for > 6 months (RR 1.27, 95% CI 1.05-1.55, P = 0.01) and epoetin alpha (RR 1.07, 95% CI 1.01-1.14, P = 0.03). The incidence of thrombo-vascular adverse events was higher in patients using ESA than in controls (RR 1.53, 95% CI 1.27-1.86, P < 0.0001). The ESA group was more effective in improving anemia in cancer patients (MD 1.20, 95% CI 0.77-1.63, P < 0.00001). The blood transfusion needs of patients in the ESA group were significantly lower (RR 0.52, 95%CI 0.44-0.60, P < 0.00001). There was no statistically significant difference between the two groups in disease progression-related conditions (HR 1.03, 95%CI 0.95-1.12, P = 0.52). ESAs increase the risk of mortality and the incidence of thrombo-vascular adverse events in breast cancer patients, while reducing their anemia symptoms and transfusion requirements. Registration PROSPERO CRD42022330450. |
| WOS关键词 | EPOETIN-ALPHA ; PHASE-III ; DARBEPOETIN ALPHA ; DOSE-DENSE ; ANEMIA ; CHEMOTHERAPY ; SURVIVAL ; RECEPTOR ; OUTCOMES ; TRIAL |
| 资助项目 | Natural Science Foundation of Liaoning Province[2020-MS-038] |
| WOS研究方向 | Research & Experimental Medicine |
| 语种 | 英语 |
| WOS记录号 | WOS:000876935400003 |
| 出版者 | SPRINGER-VERLAG ITALIA SRL |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/303014]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Sun, Xue |
| 作者单位 | 1.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 3.Gen Hosp Northern Theater Command, Dept Res & Training, 83 Wenhua Rd, Shenyang 110016, Peoples R China 4.Gen Hosp Northern Theater Command, Dept Pharm, 83 Wenhua Rd, Shenyang 110016, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wu, Tong,Tong, Zhenhua,Ren, Tianshu,et al. Effect of erythropoiesis-stimulating agents on breast cancer patients: a meta-analysis[J]. CLINICAL AND EXPERIMENTAL MEDICINE,2022:13. |
| APA | Wu, Tong,Tong, Zhenhua,Ren, Tianshu,Xie, Danni,&Sun, Xue.(2022).Effect of erythropoiesis-stimulating agents on breast cancer patients: a meta-analysis.CLINICAL AND EXPERIMENTAL MEDICINE,13. |
| MLA | Wu, Tong,et al."Effect of erythropoiesis-stimulating agents on breast cancer patients: a meta-analysis".CLINICAL AND EXPERIMENTAL MEDICINE (2022):13. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。